Rett syndrome: 2026 so far

Evidence shifted from side-effect signals to real-world persistence patterns.

In the months covered, several real-world datasets and a clinic chart review added detail on how trofinetide is used outside clinical trials (research studies with set rules), including how often people keep taking it and what gets in the way. A retrospective clinic review (a look back at medical records) described caregiver-reported improvements over 3-6 months along with frequent gastrointestinal side effects (stomach and bowel problems), especially diarrhea and also vomiting. Some people stopped early. The report also described dose titration (slowly adjusting the dose) and supportive strategies. Spontaneous adverse-event reporting (voluntary side-effect reports sent in after a drug is used) also highlighted early-onset GI complaints, often within the first month. US claims/pharmacy analyses (insurance billing and pharmacy records) then showed persistence of about half overall in broader datasets and about two-thirds in ages 2-4. In those records, use was concentrated in younger patients managed by specialists, and many adults and males were untreated. The claims data could not explain why people stopped or restarted. This helps set expectations that real-world trofinetide use often involves weighing day-to-day changes against common GI side effects and mixed continuation over months.

Research covered in: January 2026, May 2026, June 2026, July 2026, August 2026

Small case series expanded into a small open-label study.

In the months covered, fenfluramine came up twice as an early human signal for drug-resistant epilepsy (seizures that stay hard to control with medicines) in MECP2-related Rett syndrome, first as a 4-child case series (a report describing a small group) and later as a small open-label study (everyone knows they are receiving the drug; no comparison group). Both reports linked fenfluramine add-on treatment with substantial seizure reductions in many participants. The later study also reported caregiver- and clinician-noted changes in sleep and daytime breathing symptoms, without a comparison group. Side effects were common in the open-label study, most often sleepiness, and also diarrhea or motor restlessness. The small sample sizes limit what can be concluded about safety across the broader Rett population. This means fenfluramine is being explored as an add-on option for hard-to-control seizures in Rett syndrome, but the evidence in these reports is still small and uncontrolled.

Research covered in: February 2026, September 2026

Reports increasingly centered outcomes on family priorities and function.

In the months covered, several surveys and a clinician consensus put more focus on day-to-day function and caregiver experience, not only symptom counts. A family quality-of-life study reported average family quality of life below a satisfaction threshold, with emotional well-being as the lowest domain. A caregiver survey across countries highlighted caregiver priorities for meaningful change, including communication, motor function, and independence in daily activities. It also reported that key losses are often already present by age 6. Other caregiver-focused reports described sleep problems linked to worse family relations in one cohort (a group followed or studied together). In a small Spanish survey of families of children with Rett or Angelman syndrome, perceived speech-language therapy quality was tied to resources and therapist empathy, and many families reported perceived communication gains after early services; Rett-specific findings were not reported separately. This supports follow-up and research that measure everyday abilities and family-defined meaningful outcomes, while the evidence described here remains descriptive rather than comparing one intervention against another.

Research covered in: February 2026, April 2026, May 2026, August 2026

Measurement work moved toward shorter, more usable recordings and clearer trajectories.

In the months covered, studies worked on more practical ways to track Rett features over time, with an emphasis on feasibility and clearer interpretation rather than showing treatment effects. Long-term questionnaire work suggested behavioral/emotional symptom scores can decline modestly with age in large datasets. Smaller studies reported age-linked decreases in caregiver-reported breathing abnormalities and hand stereotypies (repetitive hand movements) in one sample but not in another. They also highlighted that different raters can score the same person differently. EEG (electroencephalogram, a test that records brain electrical activity) studies reported that automated artifact correction (computer-based removal of noise from the signal) kept far more usable data than rejection-based approaches. They also suggested stable resting EEG features may be obtainable from roughly 1-2 minutes of clean data. Separate studies linked sensory symptoms to less consistent brain-response timing and described elevated transient beta events (brief bursts of faster brain activity) in many children with Rett and related genetic conditions. This points toward research tracking that is becoming easier to do and more standardized, even though these reports did not present the measures as tools for guiding individual day-to-day care.

Research covered in: January 2026, April 2026, May 2026, July 2026, August 2026

Multiple lab and animal approaches targeted MeCP2 or breathing/motor pathways.

So far in 2026, many proposed treatment directions were still preclinical (tested in cells or animals, not people). These mouse and cell studies aimed either to restore MECP2 function or to improve specific symptom areas such as breathing, movement, and seizures. Reported approaches included MECP2 splicing/isoform switching in models, anticodon-engineered tRNAs (engineered transfer RNAs designed to help cells read genetic instructions differently) to read through certain MECP2 nonsense mutations in cells, and AAV9 delivery with focused ultrasound in mice (a gene-delivery approach paired with targeted ultrasound), with a noted concern about possible MeCP2 overexpression. Mouse studies also targeted pathways such as PTP1B, leptin signaling, microglial metabolism/inflammation, KCC2 activation, and mGlu7 modulation. Additional animal work explored neuromodulation (changing nerve activity using stimulation), including VNS paired with sound, and drugs such as metformin and isradipine in models. One translational example showed that an HRH3-targeting drug approach produced little to no behavioral improvement in mouse models, even though HRH3 levels were reduced in most Rett brain samples. This highlights that not every biological lead turns into symptom benefit in early testing, and none of these approaches provided human efficacy evidence in the reports covered.

Research covered in: February 2026, March 2026, April 2026, May 2026, June 2026, July 2026, August 2026, September 2026